Santarus SNTS announced today that the U.S. Food and Drug
Administration (FDA) has approved UCERIS™ (budesonide)
extended release tablets for the induction of remission in patients with
active, mild to moderate ulcerative colitis. The company expects to
commence the commercial launch of UCERIS in March 2013.
UCERIS contains budesonide, a corticosteroid, in a novel oral tablet
formulation that utilizes proprietary MMX® multi-matrix
system colonic delivery technology. The approved dosing regimen for
adult patients is one 9 mg tablet taken orally once daily in the morning
for up to 8 weeks. UCERIS was developed in collaboration with Cosmo
Technologies Limited, a subsidiary of Cosmo Pharmaceuticals S.p.A.
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in